{"name":"Zhejiang Genfleet Therapeutics Co., Ltd.","slug":"zhejiang-genfleet-therapeutics-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"GFH018","genericName":"GFH018","slug":"gfh018","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"GFH312 200 mg","genericName":"GFH312 200 mg","slug":"gfh312-200-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"GFH018","genericName":"GFH018","slug":"gfh018","phase":"phase_2","mechanism":"GFH018 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"GFH312 200 mg","genericName":"GFH312 200 mg","slug":"gfh312-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNQW03MVJQQlNaN1drRkxmM19Ta2hBUG9aSS14WE1WMlhvLWVYSDE1QU5hbUJoeExrWVowVU9oNnY5M1BUQ2hzM2RlTXN5dmN5OFBFWVp2ajZtMlV0X3Ftam00aHBYeHhUck9HaWd0bG1FMGd0ekV6Tm5pTGFrNjJCcmlkZ0FGcHFwQ3NCVFlNdllLN3IycEE?oc=5","date":"2026-03-24","type":"earnings","source":"openPR.com","summary":"Atherosclerotic Cardiovascular Disease Market: Expanding Revenue Landscape to 2034 - DelveInsight - openPR.com","headline":"Atherosclerotic Cardiovascular Disease Market: Expanding Revenue Landscape to 2034 - DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQX1VuWmh5WWpPdWtKbXdKTVN0U2dlSXpDSmpRQ1pWR0l4SlRjN0dKamhCd0w5Zmk5V0pXSE4wOU8xRXNlQnY0cUpnalB0ejdfTE4tSmlPelVEQTdnZGFaemlWYXdZZmJzUndieUFGTmdVT3BhYWdMaVV2RU1iQ0tkUDRyb01hMWZqcDNKa0EzLXd6LVhDeDNlR2FlUThQVTc4TWFKdU1OSU1GUGpfZjBCRmZwMmhYMmJHMl9lMnJOdVpwWEZIaUFQT3RTZHJBSmtRTW5SRTlXa24yejlRQlozcklNWV9zS1hQQmRBZDJRdVRzZTdZVGpVMnZQaFZ6M0pDc1NDOHIycTQ5QQ?oc=5","date":"2023-09-26","type":"pipeline","source":"PR Newswire","summary":"Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight - PR Newswire","headline":"Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOak05RFNibTVMNU5ZSDR2RERnVkVDNHZEWXlMUE1oeWZHbWdqeXJsR2ZyV0ZsMmxtSXJqODBxMEVtR0dYSzBBTnMtNE02Ml9sZ1RFYXF3NWU4ek1TSTVBMHhMLVJ4d29KZzlETFVueHNZVnY1SENUazZIb1BGbER5ZGlnc0RWWllZSjA0VjJwS2MydjNNLUI2OUxlcW5IMjJWcjBFU0pENTY4ZjVaVzIxb2tubC1PVG1FejFpWWxXRGo0RlBBejN6ODBtLWlTUzZvQ1RvY1RyVUZMMmV4NTdCbTl2NXdPSkVHOFR6RThaUHk1eDh3NFRrZ2lsTVN6S0hIbUg1MDhPVHZ6d040UDZyakRZYWY1eDNORHQ3YmJsY25paGtVamJOY3dvVmxDb0hrTWxj?oc=5","date":"2023-08-02","type":"pipeline","source":"PR Newswire","summary":"Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring, Novartis, Merck, Amgen, Ionis , BioMarin, AstraZeneca - PR Newswire","headline":"Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring, Novartis, Me","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}